Shareholders in Bannockburn-based drug company Baxalta and Irish firm Shire voted Friday to approve the $32 billion merger of the two firms.
The combined company, which will be run from Shire’s Dublin headquarters, aims to be a world leader in treating hemophilia and other rare diseases, and will benefit from Ireland’s lower corporate tax rate.
Announced in January, the deal is expected to save around $250 million a year in corporate administrative functions, Shire said. The merger was sealed after the companies determined it would not be blocked by U.S. tax laws that attempt to prevent tax avoidance via so-called corporate inversions that ship profits to lower tax jurisdictions.
Ludwig Hantson, Baxalta’s CEO, will step down, and the merged company will be known as Shire and be run by Shire CEO Flemming Ornskov. Shire’s U.S. offices are based in Lexington, Mass., and the company has not said what will happen to the 800 workers at Baxalta’s Bannockburn offices.
Full Content: Chicago Tribune
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Pfizer Settles Remaining Effexor XR Antitrust Claims for $25.5 Million
Apr 29, 2024 by
CPI
South Korean Regulator Approves LG Uplus and Kakao Mobility EV Charging Venture
Apr 29, 2024 by
CPI
Federal Judge Dismisses Doctors’ Antitrust Suit Against Ohio Health System
Apr 29, 2024 by
CPI
Paramount CEO Bob Bakish Steps Down as Merger Inches Closer
Apr 29, 2024 by
CPI
EU Brands Apple’s iPadOS as Gatekeeper in Tech Crackdown
Apr 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI